|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC
|
|
|
|
Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that's going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I'm going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I feel like it's good news, …
|
|
|
|
|
|
|
|
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron
|
|
|
|
Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I've seen many companies even go under. That's bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy companies that are doing much …
|
|
|
|
|
|
|
